Bristol Myers Squibb (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Opdivo® (nivolumab) in combination with Yervoy®…
Amgen (NASDAQ: AMGN) has announced that Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced its commitment to supporting the global response to the mpox health emergency by providing diagnostic tests specifically developed for mpox, formerly known as…
AbbVie (NYSE: ABBV) has announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for adult patients with relapsed or refractory (R/R) follicular…
Eli Lilly and Company (NYSE: LLY) announced today positive top-line results from the SURMOUNT-1 three-year study, which evaluated the long-term efficacy and safety of tirzepatide (Zepbound® and Mounjaro®) for weight…
Medea Inc., a leading medical products and pharmaceutical distribution company, is at the forefront of a major initiative to tackle the opioid crisis. The company is partnering with CalOptima Health…
UptimeHealth, a leader in healthcare technology solutions, is excited to announce a strategic partnership with Darby Dental Supply, a top dental distributor in the U.S. This collaboration introduces Darby Dispatch,…
Daiwa Health Development, Inc. Announces Webinar with Dr. Fred Pescatore on Clinical Applications of RBAC Daiwa Health Development, Inc. is thrilled to host an upcoming webinar featuring Dr. Fred Pescatore,…
AmorSui, a cutting-edge personal protective equipment (PPE) brand committed to safeguarding both people and the planet, has announced a successful $3.5 million seed funding round. This investment will propel AmorSui’s…
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company specializing in novel small molecule therapeutics from its boron chemistry platform, has announced the adoption of a limited-duration stockholder rights plan. This…
AstraZeneca’s IMFINZI® (durvalumab) Approved in the US for Comprehensive Treatment of Resectable Non-Small Cell Lung Cancer AstraZeneca has announced that IMFINZI® (durvalumab), in combination with chemotherapy, has received approval from…
Agendia is pleased to announce that it has achieved certification from the European Union (EU) In Vitro Diagnostic Medical Device Regulation (IVDR) for three of its products: the MammaPrint® FFPE…